<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03229954</url>
  </required_header>
  <id_info>
    <org_study_id>4-2017-0149</org_study_id>
    <nct_id>NCT03229954</nct_id>
  </id_info>
  <brief_title>Intravenous Iron Isomaltoside 1000 (Monofer®) Compared With Oral Iron in the Treatment of Postgastrectomy Anemia: An Open-label Randomized Controlled Trial</brief_title>
  <official_title>Intravenous Iron Isomaltoside 1000 (Monofer®) Compared With Oral Iron in the Treatment of Postgastrectomy Anemia: An Open-label Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Iron deficiency anemia is a common complication in patients who underwent gastrectomy and&#xD;
      leads to a deterioration in patient's quality of life. Therefore iron supplementation is one&#xD;
      of the important treatments in postgastrectomy patients.&#xD;
&#xD;
      Taking an oral iron is an option for iron supplementation, but the postgastrectomy patients&#xD;
      has poor absorption of iron due to their anatomic change. Accordingly, intravenous iron&#xD;
      supplementation has been emerged as another treatment option, but there are only a few&#xD;
      studies to evaluate the efficacy of intravenous iron supplementation compared with oral iron&#xD;
      in patients underwent gastrectomy.&#xD;
&#xD;
      Therefore, this study aims to evaluate the iron supplementation method as intravenous&#xD;
      injection of iron isomaltoside compared with oral iron in the treatment of postgastrectomy&#xD;
      anemia.&#xD;
&#xD;
      Gastric cancer patients who underwent curative gastrectomy more than 1 year ago and&#xD;
      hemoglobin level lower than 11 g/dL will be included in this trial. After the registration,&#xD;
      the patients will be randomly assigned to intravenous iron (n = 179) or oral iron groups (n =&#xD;
      179).&#xD;
&#xD;
      Calculated dose of iron isomaltoside using Ganzoni formula will be injected intravenously in&#xD;
      intravenous iron group and 160 mg/day of ferrous sulfate for 12 weeks will be taken in oral&#xD;
      iron group. Hemoglobin and iron profiles at baseline and weeks 2, 4, 8, and 12 and quality of&#xD;
      life score at baseline and weeks 12 period will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date type="Actual">August 28, 2017</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline Hemoglobin at 2,4,8 and 12 weeks</measure>
    <time_frame>at Baseline and weeks 2, 4, 8, and 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum iron</measure>
    <time_frame>at Baseline and weeks 2, 4, 8, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum ferritin</measure>
    <time_frame>at Baseline and weeks 2, 4, 8, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum transferrin</measure>
    <time_frame>at Baseline and weeks 2, 4, 8, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transferrin saturation</measure>
    <time_frame>at Baseline and weeks 2, 4, 8, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL (quality of life) of the patients</measure>
    <time_frame>at Baseline and weeks 2, 4, 8, and 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">358</enrollment>
  <condition>Post Gastrectomy Anemia</condition>
  <arm_group>
    <arm_group_label>IV iron (Monofer) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Iron isomaltoside(Monofer) will be injected intravenously and injection dose will be calculated using Ganzoni formula.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral iron group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ferrous sulfate(Feroba-YOU) 160mg/day for 12 weeks will be taken per oral.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iron isomaltoside (Monofer) intravenous infusion</intervention_name>
    <description>The investigational drug is a newest formulation of intravenous iron. The drug, iron isomaltoside (Monofer), will be infused one single high dose with infusion time more than 30 minutes (&lt; 1,000 mg) or 60 minutes (≥ 1,000 mg). The dosage is determined using the Ganzoni formula and divided when the calculated dose exceeds 20 mg/kg.&#xD;
If the calculated dose exceeds 1,500 mg, the patient will be excluded from trial for patient safety.</description>
    <arm_group_label>IV iron (Monofer) group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferrous sulfate(Feroba-YOU) per oral</intervention_name>
    <description>160 mg/day of ferrous sulfate (Feroba-YOU) will be taken per oral for 12 weeks.</description>
    <arm_group_label>Oral iron group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥20 years of age&#xD;
&#xD;
          -  Underwent gastrectomy for stage I or II of primary gastric adenocarcinoma&#xD;
&#xD;
          -  Hb ≤11.0 g/dL at least one year after surgery&#xD;
&#xD;
          -  Willingness to participate after signing informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Calculated dosage using the Ganzoni formula &gt;1,500 mg&#xD;
&#xD;
          -  Any medical condition may have caused the patient to be unsuitable for the completion&#xD;
             of the study or placed the patient at potential risk from being in the study&#xD;
&#xD;
          -  Underwent chemotherapy or on chemotherapy&#xD;
&#xD;
          -  Drug hypersensitivity to iron isomaltoside&#xD;
&#xD;
          -  Active acute or chronic infections&#xD;
&#xD;
          -  Known intolerance to oral iron treatment&#xD;
&#xD;
          -  History of anemia due to extensive bleeding or causes other than iron deficiency&#xD;
&#xD;
          -  Untreated vitamin B12 or folate deficiency&#xD;
&#xD;
          -  Blood transfusion, Erythropoiesis stimulating agents(ESA), oral iron or intravenous&#xD;
             iron treatment within 4 weeks prior to screening&#xD;
&#xD;
          -  History of bone marrow suppression treatment, active Hepatitis B or C, HIV or&#xD;
             hematologic disorder other than iron deficiency&#xD;
&#xD;
          -  Iron overload, hematochromatosis or hemosiderosis&#xD;
&#xD;
          -  Pregnancy or nursing&#xD;
&#xD;
          -  Creatinine clearance rate using Cockcroft-Gault formula &lt;30 mL/min&#xD;
&#xD;
          -  Participation in any other clinical study within one month prior to screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Surgery, Yonsei University College of Medicine, Seoul, Korea</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>July 23, 2017</study_first_submitted>
  <study_first_submitted_qc>July 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2017</study_first_posted>
  <last_update_submitted>January 17, 2019</last_update_submitted>
  <last_update_submitted_qc>January 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron isomaltoside 1000</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

